Researchers propose deep trawl of DNA to help uncover the causes of ME/CFS (Simon McG blog)

This is exciting, and crucial, research. Given that we have both the ICC criteria and recent work on characterising PEM, I think it'll be possible to design a screening tool that will rule out at least some people with other conditions or who have fatigue but not PEM.
 
Thanks, that is the kind of thing I am talking about.

This is very interesting and not something I had appreciated or understand. If GWAS had been available before the discovery of, say, HIV, how would GWAS have helped to identify it? My understanding is that, with a tiny number of exceptions, without treatment, anyone who is infected with HIV will eventually develop AIDS, regardless of their genes. Presumably there may be SNPs which might be helpful in identifying genes which affect behavioural characteristics which might increase the chances of being infected with HIV but I don’t understand how they could have helped to identify HIV.
A good question. As you say, the problem is that the infection rate of those exposed is very high, with only a few resistant to it. In this case conventional genetics, comparing at risk people got infected and the minority Who did not it’s probably more relevant.

Apparently, GWAS have turned up additional relevant genetic differences, in addition to those from conventional genetic studies. But as I’m struggling with a migraine I’m afraid you will have to do your own googling on this…

(I would expect the genetic differences identified to include those affecting genes involved in recognising the HIV virus as well as those that are expressed in T-helper cells, which are the cells that HIV infects. In fact, T-helper cells were only discovered as result of studying HIV)


I think this is a hugely exciting project.… If we all pull hard together and do everything we can to spread the word about the study,…
I have no MEGA qualms about this at all, with Chris Ponting leading. I really hope it gets funded and I'll be first in line to spit in a tube when when and if that time comes...
clip_image001.png

What I especially like is that getting spit from even the most severe patients should be possible and that they will presumably be able to be included.
clip_image001.png
thanks, Sasha. I know people had so many concerns about MEGA very understandable reasons. I think the study could be hugely important.

And I love that everybody can take part in including the severely affected who are normally excluded from studies.

Is it that each variant has a small effect or could it be that combinations of variants have an effect but not necessarily single ones?
that's an interesting question and I don't know if it's possible to look at that.

However, the examples I've seen (in my limited experience of the literature) have been of variants having an independent affects, as in the IL-23 Pathway Mentioned in the Blog:

Other autoimmune disease
Researchers have compared GWAS results from different illnesses to see if they have something in common – and autoimmune diseases often do. Findings from these studies have led to the identification of a common pathway for several diseases, one that includes an immune-regulating molecule called IL-23. As a result of this insight, existing drugs that are used to inhibit the IL-23 pathway in other diseases have become a mainstay treatment for several autoimmune conditions, including psoriasis and ankylosing spondylitis.

This is exciting, and crucial, research. Given that we have both the ICC criteria and recent work on characterising PEM, I think it'll be possible to design a screening tool that will rule out at least some people with other conditions or who have fatigue but not PEM.
thanks, Kitty

[/QUOTE]
 
Not read it yet but thought it looked like it might add to the conversation.
Benefits and limitations of genome-wide association studies

Genome-wide association studies (GWAS) involve testing genetic variants across the genomes of many individuals to identify genotype–phenotype associations. GWAS have revolutionized the field of complex disease genetics over the past decade, providing numerous compelling associations for human complex traits and diseases. Despite clear successes in identifying novel disease susceptibility genes and biological pathways and in translating these findings into clinical care, GWAS have not been without controversy. Prominent criticisms include concerns that GWAS will eventually implicate the entire genome in disease predisposition and that most association signals reflect variants and genes with no direct biological relevance to disease. In this Review, we comprehensively assess the benefits and limitations of GWAS in human populations and discuss the relevance of performing more GWAS.
Paywall, https://www.nature.com/articles/s41576-019-0127-1
Sci hub, https://sci-hub.se/10.1038/s41576-019-0127-1
 
I understand people's frustration at the time-scale but the faster patients sign up (and spit!), the faster it will get done. If we all pull hard together and do everything we can to spread the word about the study, I think we could recruit on a large scale, pretty quickly. Even five years ago I don't think we could have, but in these days of #MEAction and the huge amount of online networking that we now have, I think we're ready for this.
@Simon M. :thumbup:

As U.K. ME/CFS Biobank will be involved, I am sure that some sort of abbreviated version of their Participant Questionnaires would supply sufficient information:
to ascertain whether PEM is experienced,
where & when pain is experienced, whether constant, regular, daily......,
request a list of other diagnoses the patient may have,
whatever particular info the researchers may find useful.
There could be a quick version (for severe) or more detailed questionnaire (for those able to complete).
Please shout @Simon M if you need any patient guinea pigs to ‘test’ a questionnaire!


I had already thought of:
local support groups
regional #MEAction group
twitter friends
FB groups
Charity websites.......sure we could pull together to get the samples.
 
I think this is a hugely exciting project......

I understand people's frustration at the time-scale but the faster patients sign up (and spit!), the faster it will get done. If we all pull hard together and do everything we can to spread the word about the study, I think we could recruit on a large scale, pretty quickly. Even five years ago I don't think we could have, but in these days of #MEAction and the huge amount of online networking that we now have, I think we're ready for this.

I have no MEGA qualms about this at all, with Chris Ponting leading. I really hope it gets funded and I'll be first in line to spit in a tube when when and if that time comes :balloons::balloons:

And I will be second in the Virtual Queue @Sasha

Fundraising possibilities @Simon M :

1) Any return envelope (pre paid from U.K.) for the pot could include a message:

“Please add a (xx)p stamp from the U.K. and help our research funds stretch a little further”

2) Consider asking for a voluntary donation for “the kit” (i.e. the survey/pot/SAE)?

Not at the application point, but include a donation slip (to include gift aid opportunity),
Or the link to a Fundraising Page, in with “the kit”

saying “if you are able to donate £5 (or more) towards this research, that would go towards the tests and if you can spare more that that would help a fellow PwME, who perhaps is not in a position to donate cash, just their sample”

^^^^ I'm thinking along the lines of Jack Monroe's Tin Can book - buy your own copy and pay for another copy which can be donated to the food bank for someone else who can't afford it.
 
Thank you @Simon M !!! Some questions if you are able to pass them on.

1. Would the study need controls or could it leverage and use labs/sequencing chips from previous GWAS studies to keep costs down.

2. Would patients submit a survey to try and better group data being that we are a likely hetergenous group. I'm thinking this is also a good chance to leverage some of the ME Biobank data surveys that they do. And also best results are obtained with a well defined case and control group - which is likely hard with 20,000 patients. Needs some good GWAS experience to well define the study I imagine.

3. Would it be a mail in saliva sample or lab blood sample?

4. Would it be UK only or wider? I assume the population stratification of control group needs to match that of patient group so ties into (1) above.

5. Approximate cost per sample? I have no idea how much a GWAS study would cost.

6. What are @Chris Ponting thoughts on the value of GWAS as described vs WGS of families with multiple people effected to find the significant genes. I'd like to understand the pros and cons. Probably both have a place......

Sorry, I've been away on vacation and so have not been following these discussions. Simon FWIW I think you've done an excellent job of explaining the strengths and limitations of a GWAS. On this issue of GWAS versus WGS (whole genome sequencing): GWAS asks 'what DNA letters that are *common* in the population predict ME status?' WGS asks 'what DNA letters that are *rare* (or even unique to the individual) predict ME status?' The difference comes from the GWAS technology sampling only a million or two letters for any person, whereas WGS reads out all 3 billion (or tries to). This GWAS technology is considerably cheaper than the WGS one and so can be applied at scale (thousands of people) whereas WGS of pwME's DNA is being done on dozens of people. Because of the large scale of GWAS it becomes feasible to robustly (i.e. statistically) say that a particular DNA variant is more likely to be in pwME than in healthy controls. Typically, this cannot be done with the dozens of WGS from pwME. Hope this is OK.

Another question I think has been "Will these be real cases of ME/CFS?" Yes! We will be consulting widely over this issue (of course) before the study plan is finalised, but the current idea is to start with the CureME Biobank inclusion/exclusion criteria (https://cureme.lshtm.ac.uk/researchers/inclusionexclusion-criteria/). A GWAS where each of the ~20k participants is assessed clinically would not be possible (too expensive) so the criteria used would need to be validated by subsampling participants and clinically assessing them. We expect different genetic contributions to ME risk ("genetic heterogeneity") and so do not wish to define ME using the narrowest criteria ("phenotypic homogeneity"). The narrowest criteria would disallow any chance of reaching 20k participants. I want to say - strongly - that PEM will be a primary inclusion criterion and that patient/carer groups will be involved centrally in drawing up the final study design and inclusion/exclusion criteria. I was around on the periphery of MEGA and see how some things need to be done better for this project. (We also need a name for the project - any ideas?)
 
Thanks for taking the time to reply, Chris – and for all your work on this.

Can you shed any light on whether/how GWAS could help if it transpired that ME was caused by a pathogen, as I asked above? My limited understanding is that it would help if ME was triggered by a pathogen in genetically predisposed individuals but that it would have been unlikely to help with the discovery of HIV or the prion which causes vCJD. Is that correct?

I was around on the periphery of MEGA and see how some things need to be done better for this project. (We also need a name for the project - any ideas?)
I think many of us are fed up with annoying acronyms like MEGA, PACE, GETSET etc. I would chose something that sounds dry, serious and scientific like the ME GWAS study.

Off topic, but I’m also hoping that the CMRC might be persuaded to change its name to reflect its new direction and focus.
 
Hi Robert. Yes, absolutely correct. Because the trigger (the pathogen) is not "written into" the DNA of individuals, we would not "see it". But what we can do is to detect what DNA letters predispose pwME to not recovering from these triggers. Knowing what the molecular/cellular deficit in recovery is becomes the first step to reversing the deficit.

OK: I like the ME GWAS. Nice and simple. I'll see what others thing.

CMRC: For clarity, "ME GWAS" is not a CMRC project. It is a joint venture between scientists such as myself and from the CureME Biobank, charities and pwME. There is a problem with losing the "C" in "CMRC" though because it then reverts to the "MRC" who are a main grant giving body! I'm less interested in names, and more interested in what can (needs to) be done. But I appreciate that, to some, names can evoke strong reactions!
 
Will patients from outside the UK be able to participate? Have you considered working with researchers in other countries to reach the 20k target faster? Or is that not viable.
 
I think many of us are fed up with annoying acronyms like MEGA, PACE, GETSET etc. I would chose something that sounds dry, serious and scientific like the ME GWAS study.
Good point about acronyms.

But bear in mind that this project might need to recruit 20,000 people (more, since some won't meet the selection criteria). So we will be going well beyond the current ME online community, and reaching people who don't know much about research. I think ME GWAS won't mean anything to many pwME reading an article about the study in their local paper or hearing it on the radio. Maybe something with DNA or genetic in the title, something that most will recognise.

Along with ME, maybe: many people, esp outside the UK, won't recognise "ME" as they will have been told they have CFS. Even most US researchers (sadly) use CFS not ME or mecfs.

But name ideas are not my forte.
 
Will patients from outside the UK be able to participate? Have you considered working with researchers in other countries to reach the 20k target faster? Or is that not viable.
Yes, my main concern is meeting this target. One thing that I need to find out is what are the restrictions from recruiting from outside the UK. This will be defined by the ethics committee governing the study so we won't know for a while.
 
I keep reading GWAS as Gulf War.. so it has been confusing for me.

I would love to be able to participate in this study. I am in New Zealand though. It would be great if we could have a cohort that are a mix of patients from all around the world as one cohort group. I've never been in a ME study and would love to have the opportunity if it is possible.
 
I would love to be able to participate in this study. I am in New Zealand though. It would be great if we could have a cohort that are a mix of patients from all around the world as one cohort group.
Make that two of us :thumbsup:

Also, if done well, the recruitment process could double as a sort of PR exercise for ME as a serious condition. Along the lines of "Wow! Somebody is prepared to look at the dna of 20,000 people - that must be something nasty they're looking for."

For example, the various charities may be able to get a few articles into the general press for the occasion. And, if it's legal, GPs could be asked to think of any ME patients they might have - yes, doctor, those heartsink ones you prefer not to think about - and be asked to give them an information sheet on the study.
 
What facilities/equipment/expertise would be needed to analyse the samples? If the project could be made 'modular' in some way, so that it's exact process could be replicated almost anywhere, could samples then not be analysed in different countries and the data pooled?
 
It seems there has just been a massive GWAS study published by King’s College London on anorexia. It had large UK cohort and large worldwide cohort. Some of the funding looks to have been the NIHR.
https://www.nature.com/articles/s41588-019-0439-2
Anorexia: Origins are complex mix of mind and body https://www.bbc.co.uk/news/health-48989359

I've added a thread on this here:
https://www.s4me.info/threads/genom...ychiatric-origins-for-anorexia-nervosa.10396/
 
Back
Top Bottom